LUNA

Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 14, 2023
Independence, Research, NYSE, Telephone, Gynaecology, Freezing, Cleveland Clinic Akron General, Investment, Clinic, Traction, Patient, LUNA, FDA, Organ (biology), Intelligence, Machine learning, CIS, Mayo Clinic Hospital (Rochester), GAAP, Communication, RESEARCH, Growth, Commonwealth, Dentistry, Video game, Security (finance), Nursing, Cryptocurrency

We anticipate reaching important milestones in the upcoming quarters,” said Anthony Fernando, Asensus Surgical President and CEO.

Key Points: 
  • We anticipate reaching important milestones in the upcoming quarters,” said Anthony Fernando, Asensus Surgical President and CEO.
  • The LUNA System's development is in progress and is now entering the testing and evaluation phase before regulatory submissions.
  • Future milestones include freezing the system's design in early 2024, followed by verification and validation testing, and pilot manufacturing.
  • Revenue in the third quarter of 2023 included $0.5 million in lease revenue, $0.3 million in instruments and accessories, and $0.3 million in services.

Asensus Surgical, Inc. Announces Agreement with Flex for Design and Advanced Manufacturing Services for the LUNA™ Surgical System

Retrieved on: 
Monday, November 13, 2023
RESEARCH, Health, NYSE, Patient, FLEX, LUNA, Medco Health Solutions, Medical device, Flex

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced an agreement with diversified manufacturer Flex (NASDAQ: FLEX) for design and advanced manufacturing services for Asensus’s previously-announced LUNA Surgical System , a next-generation surgical robot platform.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced an agreement with diversified manufacturer Flex (NASDAQ: FLEX) for design and advanced manufacturing services for Asensus’s previously-announced LUNA Surgical System , a next-generation surgical robot platform.
  • Flex will provide a range of services across LUNA’s product lifecycle to enable Asensus Surgical to deliver the platform at scale, faster.
  • These include design for manufacturing services to assess and improve LUNA’s manufacturability, ensuring a seamless and fast transition from product design to ramp to full-scale manufacturing.
  • “Our collaboration with Asensus Surgical will enable them to deliver the LUNA platform to market faster, reliably, and sustainably, making next-generation surgical robotics solutions more accessible to patients worldwide.”

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Retrieved on: 
Thursday, November 9, 2023
Drug development, Three Months, Ophthalmology, Safety, Annual general meeting, Research, American Academy of Ophthalmology, Gene, Allergan, Investment, Anti-VEGF, American Academy, Data, Patient, Cell, LUNA, OPTIC, AAO, AMD, NHP, CMC, Injection, CST, Inflammation, Pharmaceutical industry, Dietary supplement, Medical imaging, Medical device, Cryptocurrency, Adverum Biotechnologies

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • “In our OPTIC presentation at AAO, we’ve built upon our industry leading dataset in wet AMD gene therapy,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • Scientific Meeting Presentations: In October 2023, Adverum showcased non-clinical data in two presentations at the European Society of Cell and Gene Therapy 2023 Annual Meeting.
  • Stock-based compensation expense included in research and development expenses was $1.2 million for the third quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.2 million for the third quarter of 2023.

Luna Announces Third-Quarter 2023 Financial Release Date of November 14, 2023

Retrieved on: 
Friday, November 3, 2023
Telephone, Luna, Webcast, LUNA, Cryptocurrency

Roanoke, VA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Luna Innovations Incorporated (NASDAQ: LUNA) announced today it will report its third-quarter financial results for the period ended September 30, 2023, before the open of the stock market on Tuesday, November 14, 2023.

Key Points: 
  • Roanoke, VA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Luna Innovations Incorporated (NASDAQ: LUNA) announced today it will report its third-quarter financial results for the period ended September 30, 2023, before the open of the stock market on Tuesday, November 14, 2023.
  • Following the release, Scott Graeff, President and Chief Executive Officer; George Gomez-Quintero, Chief Financial Officer; and Brian Soller, Chief Technology Officer will host a conference call at 8:30 a.m. Eastern to discuss the third-quarter 2023 earnings results.
  • Participants should ask to join the Luna Innovations Incorporated conference call, conference ID 6862329, and are advised to dial in at least fifteen minutes prior to the call.
  • The webcast will be archived on the company’s website under “Webcasts and Presentations” for 30 days following the conference call.

NOUHAUS Makes its Grand Entrance to Europe Exhibiting at the Fall Maison & Objet 2023

Retrieved on: 
Friday, September 8, 2023
Parc des Expositions de Villepinte, Music, Exhibition, K-Design Award, Maison et Objet, LUNA, Aqua Blue Sport, Massage, Moon, PARC, OpenText, Interior design

In fact, it is Nouhaus' first showcase in the European exhibition, embarking its first significant entrance to the European market.

Key Points: 
  • In fact, it is Nouhaus' first showcase in the European exhibition, embarking its first significant entrance to the European market.
  • Just like watching a show, visitors will be sitting on the Nouhaus chair and be entirely immersed into the experience.
  • LUNA is a massage chair launched in January by NOUHAUS after 3 years of development, presenting artistic relaxation.
  • Yet, Maison & Objet is a major exhibition in Paris determing the present day and the future of interior design since 1995.

CLIF Partners with Top-Ranked U.S. Tennis Pro Frances Tiafoe to Launch Series of Tennis Clinics Across U.S.

Retrieved on: 
Wednesday, August 23, 2023
Sports, Philanthropy, Family, Supermarket, Training, Consumer, Food, Beverage, Primary, Secondary, Teens, Tennis, Retail, Children, Other Philanthropy, Senior, Partnership, Junior Tennis Champions Center, Education, Life, JTCC, Multimedia, LUNA, Junior tennis, Organization, Athlete, Sport, City, Sports equipment, Nursing, Frances Tiafoe, CLIF

CLIF , maker of CLIFBAR, CLIF KID, and LUNA, today announced a partnership with professional tennis player Frances Tiafoe to launch a series of community tennis clinics in cities across the U.S., providing young athletes greater access to the sport and a unique opportunity to train with Tiafoe.

Key Points: 
  • CLIF , maker of CLIFBAR, CLIF KID, and LUNA, today announced a partnership with professional tennis player Frances Tiafoe to launch a series of community tennis clinics in cities across the U.S., providing young athletes greater access to the sport and a unique opportunity to train with Tiafoe.
  • View the full release here: https://www.businesswire.com/news/home/20230823842174/en/
    CLIF partners with top-ranked U.S. tennis pro Frances Tiafoe to launch series of tennis clinics across U.S. (Photo: Business Wire)
    The clinics will take place over the next 12 months at community centers in select cities across the country, aligning with Tiafoe’s professional tournament schedule.
  • The clinics are a result of the brand’s work with the Frances Tiafoe Fund, a fund focused on bringing together tennis and education to increase access for under-resourced youth.
  • CLIF was one of the first corporate supporters of the Frances Tiafoe Fund, which was launched in July.

Asensus Shares First Quarter Results and Future Plans

Retrieved on: 
Thursday, June 1, 2023
Communication, Surgeon, CE marking, OR, Research, LUNA, PCG, Patient, Investment, KARL, ISU, FDA, GI, NYSE, Medtech, Safety, Dentistry, Video game, Pharmaceutical industry

First quarter revenue was $1 million with cash, cash equivalents, short- and long-term investments, excluding restricted cash, of approximately $57.4 million at the close of the quarter.

Key Points: 
  • First quarter revenue was $1 million with cash, cash equivalents, short- and long-term investments, excluding restricted cash, of approximately $57.4 million at the close of the quarter.
  • Asensus also surpassed 10,000 procedures on its Senhance(R) Surgical System, including a new program launched in Japan - one of the company's fastest-growing regions.
  • - Asensus received CE Mark approval for expanded machine vision capabilities on the ISU, which continues to notch praise throughout the industry.
  • "These are exciting times at Asensus," said Asensus President and CEO Anthony Fernando.

Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Insurance, CFI, Partnership, Doctor of Pharmacy, Anticipation, Optogenetics, AMD, OPTIC, European Medicines Agency, Eye, Complement, Geographic atrophy, Research, LUNA, GA, Inflammation, AAV, PRIME, Messenger, IVT, Data, Patient, Complement factor I, Investment, Annual general meeting, United Kingdom, Diagnosis, NHP, United, Medicines and Healthcare products Regulatory Agency, Innovation, FDA, Safety, Three Months, Caregiver, Pharmaceutical industry, Vaccine, Medical device, Cryptocurrency, Adverum Biotechnologies

REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • “We are pleased to announce completion of enrollment in our Phase 2 LUNA trial,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • “The LUNA study design allows us to evaluate efficacy and safety of two Ixo-vec doses, while optimizing the prophylactic steroid regimens.
  • Stock-based compensation expense included in research and development expenses was $1.4 million for the second quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the second quarter of 2023.

Luna Announces Second-Quarter 2023 Financial Release Date of August 10, 2023

Retrieved on: 
Monday, July 31, 2023
Telephone, Luna, Webcast, LUNA, Cryptocurrency

Roanoke, VA, July 31, 2023 (GLOBE NEWSWIRE) -- Luna Innovations Incorporated (NASDAQ: LUNA) announced today it will report its second-quarter financial results for the period ended June 30, 2023, at the close of the stock market on Thursday, August 10, 2023.

Key Points: 
  • Roanoke, VA, July 31, 2023 (GLOBE NEWSWIRE) -- Luna Innovations Incorporated (NASDAQ: LUNA) announced today it will report its second-quarter financial results for the period ended June 30, 2023, at the close of the stock market on Thursday, August 10, 2023.
  • Following the release, Scott Graeff, President and Chief Executive Officer; Gene Nestro, Chief Financial Officer; and Brian Soller, Chief Technology Officer will host a conference call at 5:00 p.m. Eastern to discuss the second-quarter 2023 earnings results.
  • Participants should ask to join the Luna Innovations Incorporated conference call, conference ID 6350168, and are advised to dial in at least fifteen minutes prior to the call.
  • The webcast will be archived on the company’s website under “Webcasts and Presentations” for 30 days following the conference call.

The Winners of the 2023 New Voices $150,000 POWER PITCH sponsored by Entergy are Announced!

Retrieved on: 
Wednesday, July 12, 2023
African American, Women, Consumer, Foundation, Philanthropy, PITCH, Culture, CVS, Woman, Entergy New Orleans, Multimedia, LUNA, Shaira Luna, Target, POWER, Essence, Beauty, Walmart, Entergy, MAGIC, Growth, Ecosystem, Entrepreneurship, Coca-Cola, CPR, Female, Pharmaceutical industry, Nursing

The New Voices Foundation is proud to announce the winners of the New Voices $150,000 POWER PITCH sponsored by the Entergy Charitable Foundation.

Key Points: 
  • The New Voices Foundation is proud to announce the winners of the New Voices $150,000 POWER PITCH sponsored by the Entergy Charitable Foundation.
  • View the full release here: https://www.businesswire.com/news/home/20230712120519/en/
    The New Voices Foundation presents the winners of the New Voices $150,000 POWER PITCH sponsored by the Entergy Charitable Foundation.
  • Entergy’s sponsorship is part of a $250,000 donation from the Entergy Charitable Foundation to support the work of the New Voices Foundation in expanding economic opportunities for entrepreneurs of color.
  • “New Voices Foundation advances economic equity by closing gaps in access to capital, revenue, entrepreneurial education, and networking opportunities.